Given the news towards the end of Q4 2020 of a number of successful COVID-19 vaccine discoveries, followed by expectations of an immediate rollout of a vaccination programme, and probable clarity around Brexit negotiations, we got to work quickly in early December to invest. Our belief that the small and mid-cap segment of the UK public equity market offers investment potential was corroborated within the first two weeks of SBO s launch when one of our holdings was bid for - a first for the portfolio. Calisen, a provider of energy meters and metering systems, received an offer from Coyote Bidco (a consortium consisting of investors including BlackRock Alternatives Management and Mubadala Investment Company) that was c.26% above the previous day s closing share price. Calisen s directors and KKR owned c.73% of the company and voted in favour of the deal; as such we believed limited acceptance would be required from the remaining shareholders to obtain
LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%
Wed, 20th Jan 2021 17:40
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Alliance Pharma PLC - healthcare company - Expects see-through revenue for 2020 to be down 5% on the prior year at GBP137.5 million from GBP144.3 million reported for 2019, both on a reported basis and on a constant currency basis, reflecting the impact of the Covid-19 pandemic. Underlying pretax profit for 2020 is expected to be marginally ahead of market expectations. As we progress into 2021, we look forward to regaining the strong momentum and revenue growth of recent years, and to benefiting from the additional growth opportunities that Amberen brings into the group, said Chief Executive Peter Butterfield. The acquisition of Biogix has brought Amberen into Alliance Pharma, a brand for the relief of menopause symptoms. The acquisition cre